Boehringer Ingelheim International GmbH
🇩🇪Germany
Clinical Trials
267
Active:185
Completed:25
Trial Phases
4 Phases
Phase 1:221
Phase 2:9
Phase 3:5
+1 more phases
Drug Approvals
117
NMPA:99
EMA:18
Drug Approvals
Pramipexole Dihydrochloride Tablets
- Product Name
- 森福罗
- Approval Number
- 国药准字HJ20140918
- Approval Date
- Aug 15, 2024
NMPA
Pramipexole Dihydrochloride Tablets
- Product Name
- 森福罗
- Approval Number
- 国药准字HJ20140917
- Approval Date
- Aug 15, 2024
NMPA
Pramipexole Dihydrochloride Tablets
- Product Name
- 森福罗
- Approval Number
- 国药准字HJ20140916
- Approval Date
- Aug 15, 2024
NMPA
Pramipexole Dihydrochloride Tablets
- Product Name
- 森福罗
- Approval Number
- 国药准字HJ20181121
- Approval Date
- Aug 15, 2024
NMPA
Pramipexole Dihydrochloride Sustained-release Tablets
- Product Name
- 森福罗
- Approval Number
- 国药准字HJ20140580
- Approval Date
- May 22, 2024
NMPA
Pramipexole Dihydrochloride Sustained-release Tablets
- Product Name
- 森福罗
- Approval Number
- 国药准字HJ20140581
- Approval Date
- May 22, 2024
NMPA
Pramipexole Dihydrochloride Sustained-release Tablets
- Product Name
- 森福罗
- Approval Number
- 国药准字HJ20140583
- Approval Date
- May 22, 2024
NMPA
Pramipexole Dihydrochloride Sustained-release Tablets
- Product Name
- 森福罗
- Approval Number
- 国药准字HJ20140579
- Approval Date
- May 22, 2024
NMPA
Pramipexole Dihydrochloride Sustained-release Tablets
- Product Name
- 森福罗
- Approval Number
- 国药准字HJ20140584
- Approval Date
- May 22, 2024
NMPA
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next
Clinical Trials
Distribution across different clinical trial phases (239 trials with phase data)• Click on a phase to view related trials
Phase 1
221 (92.5%)Phase 2
9 (3.8%)Phase 3
5 (2.1%)Not Applicable
3 (1.3%)phase_2_3
1 (0.4%)No trials found
News
Cathepsin C Inhibitor BI 1291583 Shows Promise in Reducing Bronchiectasis Exacerbations
Phase 2 AIRLEAF trial results indicate that BI 1291583, a cathepsin C inhibitor, reduces the risk of pulmonary exacerbations in adults with bronchiectasis.